NovMetaHealth

For Your Healthy Life, NovMetaHealth

NovCK

Pipeline
NovCK
Program Target
Cytokine Release Syndrome
Development Stage
Research
NovMetaHealth researches and develops NovCK, a new substance-based cytokine inhibitor.

NovMetaHealth is researching NovCK, a new substance-based cytokine inhibitor and it is expected to be able to treat Cytokine Release Syndrome. Which is caused by various infectious diseases including COVID-19.

N20 effect: poly I:C medication-induced BMBM activation model
N20 reducing cytokine release

NovCK Development Status

01

Clinical Development Status

02

Patent Application and Registration Status
Patents IP Protection
Cytokine inhibition patent (US)
Application
2020
Patent expiration (expected) year
(2040)